trending Market Intelligence /marketintelligence/en/news-insights/trending/NfQ1uvuYsE7YnDj4uczGOg2 content esgSubNav
In This List

Elanco acquires pig-vaccine maker Prevtec Microbia for C$78.5M up front

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Elanco acquires pig-vaccine maker Prevtec Microbia for C$78.5M up front

Elanco Animal Health Inc. acquired privately held pig-vaccine maker Prevtec Microbia Inc. for C$78.5 million plus a contingent payment option.

Montreal-based Prevtec makes the Coliprotec line of vaccine products that protect pigs against post-weaning diarrhea and symptoms caused by the E. coli bacteria. In Europe, death due to post-weaning diarrhea has an estimated cost of 15,000 per year for a 500-sow herd, Elanco said in an Aug. 1 press release.

The Greenfield, Ind.-based animal health company Elanco said the acquisition supports its efforts to build a swine products portfolio and introduce antibiotic alternatives. The company added that it will look to expand registration to other key geographies.

Elanco, which was the exclusive distributor for Coliprotec in Canada and Europe, said these vaccine products are important in Europe given the EU's direction to phase out the antibiotic colistin and zinc oxide, which are used to protect against E. coli.

Under the agreement, Elanco acquired Prevtec, including inventory and pipeline assets in an all-cash deal for C$78.5 million. Former Prevtec shareholders are also eligible to receive a contingent payment of up to C$21.5 million in the first quarter of 2022 if certain sales milestones are met in 2021.